Clinical-stage company developing innovative, precision-targeted therapeutics to improve the lives of patients with psychiatric disorders.
Engrail Therapeutics
Neurology
Total Addressable Market
Red Tree Board Member(s)
Red Tree Board Member
Heath Lukatch, Ph.D.
Red Tree Participation
Co-investor in Series B